Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With rBet v1-FV Compared to Placebo in Birch Pollen-Allergic Patients With IgE-Mediated Seasonal Allergic Rhinoconjunctivitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2014
Price :
$35
*
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Allergopharma
- 08 Mar 2013 Lead trial centre amended as reported by ClinicalTrials.gov.
- 16 Dec 2011 New trial record